Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025
To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company's website for at least 14 days.
About Revolution Medicines, Inc.Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company's pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.
Revolution Medicines Media & Investor Contact:media@revmed.cominvestors@revmed.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Pharma interest can plug NIH funding gap: Illumina CEO
Genetic sequencing company Illumina (ILMN) has had a rough few years. It has battled activist investors, faced off with the Federal Trade Commission, and, most recently, agreed to a $9.8 million settlement with the Department of Justice over a cybersecurity breach. To add to the pile: sanctions in China and the Trump administration cutting National Institutes of Health (NIH) funding, which the company relies heavily on for clinical research. The numbers don't lie. The stock is down more than 21% in the past year and sank more than 11% in after-hours trading Thursday after the company reported an earnings miss for the second quarter. The company reported $1.06 billion in revenues compared to expected revenues of $1.05 billion. Adjusted earnings per share came in at $1.19 compared to estimates of $1.01. But CEO Jacob Thaysen told Yahoo Finance he remains positive about the company's near-term growth. Why? Because, in part, pharmaceutical companies can provide a new market. "Now, we're shifting from small things to really big programs. Some of the things making up for the reduction from the NIH is kind of indirect, but pharma is getting more interest in these big programs," he said, noting that 15% of the company is exposed to government research funding. "It's not only about sequencing itself, but really using massive amounts of data ... to really identify new drug targets and understand a disease," Thaysen said. The idea to use patient data to help the pharmaceutical world was also identified by 23andMe, which recently came out of bankruptcy through a nonprofit led by founder Anne Wojcicki. Thaysen said that unlike 23andMe, which he has worked with, his company is not going to pursue drug development on its own. "We have a lot of pharma companies that are very excited to work with us," he said. In addition to genetic testing of patient samples, the company is looking at growing in the preventative side of care with cancer screenings. The oncology business, Thaysen said, will have healthy growth over the next 10 or so years. China China banned importations of the San Diego-based company's sequencing machines earlier this year as part of its retaliatory actions to Trump's tariff war. Thaysen said he is working with regulators to try to reverse that, but "in the meantime, that business is declining, and we are expecting it to be flat." In fact, though China has historically been about 10% of the company's business, it contributed to half of the decline in earnings this past week. "China was never a huge part of Illumina's business. When it was the largest, it was just around 10%. We're down to 5% of the business," Thaysen told Yahoo Finance. But because of the tariff war and China's goals to boost its domestic innovation market, Illumina has faced a setback in its market power there from local competition. "As soon as there is a Chinese alternative that is good enough, then you will see that the Chinese government is pushing for the Chinese population, the Chinese companies to use that technology," Thaysen said. He added that even with the increased competition, China is an appealing market to remain in. Analysts are still waiting to see more progress on Illumina's return to growth. Jefferies analyst Tycho Peterson said in a note to clients that the firm will reiterate its Hold rating until things settle: "While the clinical traction is encouraging, we view clarity on near-term headwinds (A&G, China, Roche) and a path to sustainable HSD growth as key to a more constructive view. Reiterate Hold." Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 minutes ago
- Yahoo
Lucid Group, Inc. (LCID) Opens Phoenix Hub, Accelerates Gravity SUV Production and Job Growth
We recently compiled a list of the 10 Best Low Cost Stocks To Buy Under $50. Lucid Group, Inc. stands tenth on our list. Lucid Group, Inc. (NASDAQ:LCID) is among the cheap stocks to buy. It is a U.S.-based luxury EV manufacturer known for its Lucid Air sedan and is expanding its footprint with the upcoming Gravity SUV and a growing emphasis on advanced technology. The company operates high-tech manufacturing facilities in Arizona and focuses on performance, efficiency, and premium features. In July 2025, Lucid Group, Inc. (NASDAQ:LCID) launched key updates to its DreamDrive Pro driver-assistance system, including new hands-free driving and automated lane change features. These enhancements, delivered via over-the-air updates, place the company among leaders in driving automation and align with its long-term push toward autonomous capabilities. The corporation also announced that Air owners will gain access to Tesla's Supercharger network starting July 31, 2025, through a NACS adapter. This dramatically improves charging accessibility for LCID drivers and addresses a core challenge for EV adoption. The business expanded its manufacturing capacity with the opening of the Phoenix Hub, acquired from Nikola Corporation. This facility will support the production of the Gravity SUV and a future midsize EV platform, and is expected to create up to 500 jobs over the next few years. On the supply chain front, Lucid Group, Inc. (NASDAQ:LCID) partnered with critical mineral producers to strengthen sourcing resilience and support sustainable vehicle production in the U.S. Looking ahead, the company is ramping up Gravity SUV production and plans a 1:10 reverse stock split aimed at attracting a broader investor base. Additionally, a new marketing campaign featuring actor Timothée Chalamet will debut in fall 2025, reinforcing the corporation's image as a premium, innovative brand. While we acknowledge the potential of LCID as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
15 minutes ago
- Yahoo
Northern Trust Second Quarter 2025 Earnings: Beats Expectations
Northern Trust (NASDAQ:NTRS) Second Quarter 2025 Results Key Financial Results Revenue: US$1.98b (down 27% from 2Q 2024). Net income: US$412.8m (down 53% from 2Q 2024). Profit margin: 21% (down from 33% in 2Q 2024). The decrease in margin was driven by lower revenue. EPS: US$2.14 (down from US$4.35 in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Northern Trust Revenues and Earnings Beat Expectations Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 4.2%. Looking ahead, revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Capital Markets industry in the US. Performance of the American Capital Markets industry. The company's shares are down 2.3% from a week ago. Risk Analysis You should learn about the 1 warning sign we've spotted with Northern Trust. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
